{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:57Z","timestamp":1791500037200,"version":"4.3.4"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jaad.2017.11.061","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:46:33Z","timestamp":1523972793000},"page":"e121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Activated mTORC1 signaling: The common driving force of type 2 diabetes and hidradenitis suppurativa"],"prefix":"10.1016","volume":"78","author":[{"given":"Valerio","family":"De Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo C.","family":"Melnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2017.11.061_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2017.08.042","article-title":"Hidradenitis suppurativa and diabetes mellitus: a systematic review and meta-analysis","volume":"78","author":"Bui","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.11.061_bib2","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1038\/cddis.2013.506","article-title":"TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists","volume":"4","author":"Blagosklonny","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jaad.2017.11.061_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/jdv.13233","article-title":"Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop","volume":"30","author":"Monfrecola","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2017.11.061_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000484408","article-title":"The magnitude of mTORC1 signalling may predict the response to isotretinoin treatment in patients with hidradenitis suppurativa","volume":"233","author":"De Vita","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2017.11.061_bib5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.11.061_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ijd.13420","article-title":"Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders","volume":"56","author":"Owczarczyk-Saczonek","year":"2017","journal-title":"Int J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217328773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217328773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:47:10Z","timestamp":1759272430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217328773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0190962217328773"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.11.061","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activated mTORC1 signaling: The common driving force of type 2 diabetes and hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.11.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.08.042","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}